Register
for More
Information

Stay informed about CLN2 disease resources, including a free epilepsy gene panel testing program that may help you diagnose CLN2 early.

Register Now ›

NEW LIVE
WEBINAR!

Click here to watch on-demand, a no–cost, live, educational webinar discussing the importance of early genetic testing in pediatric epilepsy - Insights from a CLN2 disease experience.

Watch Now ›

The Natural Course of CLN2 Disease is Rapid

Children with CLN2 disease commonly experience a complete loss of cognitive abilities, motor function, and vision within the first decade of life.1,2

See Natural History Data ›

Earlier Diagnosis is Critical & Testing is Straightforward

Given the rapid rate of progression, early diagnosis is essential to ensure that families can benefit from CLN2-specific management strategies and maximize quality time.3,4

Recognize Early Signs to Shorten Time to Diagnosis ›

Optimize Care With CLN2 Disease Management Strategies

Experts have identified CLN2 disease–specific management strategies that can greatly impact patient care and quality of life.4

View Recommendations ›

References:
1. Schulz A, Kohlschütter A, Mink J, Simonati A, Williams R. NCL diseases – clinical perspectives. Biochimica et Biophysica Acta. 2013;1832:1801-1806. 2. Mole SE, Williams RE. Neuronal ceroid-lipofuscinoses. 2001 Oct 10 [Updated 2013 Aug 1]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [internet]. Seattle, WA: University of Washington; 1993-2016. 3. Nickel M, Simonati A, Jacoby D, et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health. 2018 Aug;2(8):582-590. doi: 10.1016/S2352-4642(18)30179-2. 4. Williams RE, Adams HR, Blohm M, et al. Management Strategies for CLN2 Disease. Pediatr Neurol. 2017 Apr;69:102-112. doi: 10.1016/j.pediatrneurol.2017.01.034.